Tower Research Capital (TRC)’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.75K | Buy |
2,153
+719
| +50% | +$1.92K | ﹤0.01% | 4154 |
|
|
2025
Q1 | $11.5K | Buy |
1,434
+675
| +89% | +$5.42K | ﹤0.01% | 3532 |
|
|
2024
Q4 | $7.33K | Buy |
759
+658
| +651% | +$6.35K | ﹤0.01% | 4084 |
|
|
2024
Q3 | $1.88K | Sell |
101
-793
| -89% | -$14.7K | ﹤0.01% | 5087 |
|
|
2024
Q2 | $14.9K | Buy |
894
+452
| +102% | +$7.52K | ﹤0.01% | 3929 |
|
|
2024
Q1 | $7.68K | Sell |
442
-187
| -30% | -$3.25K | ﹤0.01% | 4167 |
|
|
2023
Q4 | $9.84K | Buy |
629
+351
| +126% | +$5.49K | ﹤0.01% | 4340 |
|
|
2023
Q3 | $13.7K | Sell |
278
-101
| -27% | -$4.99K | ﹤0.01% | 3755 |
|
|
2023
Q2 | $29.7K | Buy |
379
+288
| +316% | +$22.5K | ﹤0.01% | 3009 |
|
|
2023
Q1 | $8K | Sell |
91
-243
| -73% | -$21.4K | ﹤0.01% | 4682 |
|
|
2022
Q4 | $39K | Buy |
334
+205
| +159% | +$23.9K | ﹤0.01% | 2536 |
|
|
2022
Q3 | $23K | Sell |
129
-157
| -55% | -$28K | ﹤0.01% | 3832 |
|
|
2022
Q2 | $26K | Buy |
286
+49
| +21% | +$4.46K | ﹤0.01% | 3527 |
|
|
2022
Q1 | $37K | Buy |
237
+104
| +78% | +$16.2K | ﹤0.01% | 2972 |
|
|
2021
Q4 | $40K | Buy |
133
+24
| +22% | +$7.22K | ﹤0.01% | 2955 |
|
|
2021
Q3 | $63K | Buy |
109
+14
| +15% | +$8.09K | ﹤0.01% | 2774 |
|
|
2021
Q2 | $43K | Buy |
95
+23
| +32% | +$10.4K | ﹤0.01% | 3154 |
|
|
2021
Q1 | $38K | Sell |
72
-180
| -71% | -$95K | ﹤0.01% | 3362 |
|
|
2020
Q4 | $223K | Buy |
252
+93
| +58% | +$82.3K | 0.01% | 1622 |
|
|
2020
Q3 | $101K | Buy |
+159
| New | +$101K | ﹤0.01% | 3140 |
|